Verfügbarkeit: Uveitis and immunological disorders | Technische Universität München

Uveitis and immunological disorders: with 22 tables

Gespeichert in:

Bibliographische Detailangaben
Weitere beteiligte Personen:	Pleyer, Uwe 1957- (HerausgeberIn)
Format:	Buch
Sprache:	Englisch
Veröffentlicht:	Berlin [u.a.] Springer 2007
Schriftenreihe:	Essentials in ophthalmology
Schlagwörter:	Augenentzündung Pathogenese Uveitis Aufsatzsammlung
Links:	http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017346988&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
Beschreibung:	Literaturangaben
ISBN:	9783540307976 3540307974

Internformat

MARC


LEADER	00000nam a2200000 c 4500
001	BV035426534
003	DE-604
005	20220909
007	t\|
008	090407s2007 gw \|\|\|\| 00\|\|\| eng d
015			\|a 06,A48,1122 \|2 dnb
020			\|a 9783540307976 \|9 978-3-540-30797-6
020			\|a 3540307974 \|9 3-540-30797-4
024	3		\|a 9783540307976
028	5	2	\|a 11543800
035			\|a (OCoLC)633642010
035			\|a (DE-599)BVBBV035426534
040			\|a DE-604 \|b ger \|e rakddb
041	0		\|a eng
044			\|a gw \|c XA-DE-BE
049			\|a DE-355 \|a DE-578
084			\|a YO 7622 \|0 (DE-625)153957:12928 \|2 rvk
084			\|a 610 \|2 sdnb
084			\|a WW 240 \|2 nlm
245	1	0	\|a Uveitis and immunological disorders \|b with 22 tables \|c ed.: Uwe Pleyer ...
264		1	\|a Berlin [u.a.] \|b Springer \|c 2007
336			\|b txt \|2 rdacontent
337			\|b n \|2 rdamedia
338			\|b nc \|2 rdacarrier
490	0		\|a Essentials in ophthalmology
500			\|a Literaturangaben
650	0	7	\|a Augenentzündung \|0 (DE-588)4137370-4 \|2 gnd \|9 rswk-swf
650	0	7	\|a Pathogenese \|0 (DE-588)4115512-9 \|2 gnd \|9 rswk-swf
650	0	7	\|a Uveitis \|0 (DE-588)4062232-0 \|2 gnd \|9 rswk-swf
655		7	\|0 (DE-588)4143413-4 \|a Aufsatzsammlung \|2 gnd-content
689	0	0	\|a Augenentzündung \|0 (DE-588)4137370-4 \|D s
689	0	1	\|a Pathogenese \|0 (DE-588)4115512-9 \|D s
689	0		\|5 DE-604
689	1	0	\|a Uveitis \|0 (DE-588)4062232-0 \|D s
689	1	1	\|a Pathogenese \|0 (DE-588)4115512-9 \|D s
689	1		\|5 DE-604
700	1		\|a Pleyer, Uwe \|d 1957- \|0 (DE-588)111452120 \|4 edt
776	0	8	\|i Erscheint auch als \|n Online-Ausgabe \|z 978-3-540-30798-3 \|w (DE-604)BV022401690
856	4	2	\|m Digitalisierung UB Regensburg \|q application/pdf \|u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017346988&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA \|3 Inhaltsverzeichnis
943	1		\|a oai:aleph.bib-bvb.de:BVB01-017346988

Datensatz im Suchindex

_version_	1819319415340007424
adam_text	Chapter 1 Contact Lens-Related Corneal Infection Barry A. Weissman, Anthony J. Aldave, Bartly J. Mondino 1.1 Introduction ................ 2 1.2 Risk Factors ................. 4 1.2.1 Extended Wear .............. 4 1.2.2 Contact Lens Care ........... 5 1.2.3 Role of Hypoxia ............. 5 1.2.4 Role of Immunology ......... 5 1.2.5 Role of Orthokeratology ..... 6 1.3 Microbes ................... 6 1.3.1 Bacterial Infections .......... 6 1.3.2 Protozoái Infections ......... 7 1.3.3 Fungal Infections ............ 8 1.3.4 Viral Infections .............. 8 1.4 Treatment .................. 9 1.4.1. Bacterial Infections .......... 9 1.4.1.1 Role of Steroids ............ 10 1.4.1.2 Additional Diagnostic and Therapeutic Steps .......... 10 1.4.2 AcanthamoebaInfections ... 10 1.4.3 Fungal Infections ........... 11 1.5 Successful Treatment ....... 11 1.6 Concluding Remarks ........ 7 7 References ................. 11 Chapter 2 New insights into the Diagnosis and Treatment of Dry Eye Syndrome Miki Uchino, Murat Dogru, Kazuo Tsubota 2.1 Introduction ............... 15 2.2 Sjögren s Syndrome ........ 16 2.3 Diagnosis of Dry Eye Disease 16 2.3.1 Symptoms ................. 17 2.3.2 Assessment of Ocular Surface Epithelial Health Status ..... 17 2.3.2.1 Ocular Surface Vital Staining: Fluorescein staining ........ 17 2.3.2.2 Ocular Surface Vital Staining: Rose Bengal/Lissamine Green Staining ................... 17 2.3.3 Assessment of Tear Film Stability: InvasiveTBUT Using Fluorescein ................ 17 2.3.4 Assessment of Aqueous Tear Quantity ................... 17 2.3.5 Newer Diagnostic Tools ..... 18 2.3.6 Diagnosis of Sjögren s Syndrome ... 19 2.3.7 Ocular Features of Sjögren s Syndrome ......... 19 2.4 Treatment of Dry Eyes ...... 20 2.4.1 General Health Care in Sjögren s Syndrome ...... 20 2.4.2 Artificial Tear Solutions ...... 20 2.4.3 Autologous Serum Eye Drops 21 2.4.4 Albumin as a Tear Supplement in the Treatment of Severe Dry Eyes .......... 21 2.4.5 Lacrimal Punctai Occlusion .. 22 2.4.6 Future Therapeutic Expectations ............... 22 References ................. 23 Chapter 3 Allergic Conjunctivitis: Clinical Consequences and an Update on Understanding Its Pathophysiology Andrea Leonardi 3.1 Introduction ............... 25 3.2 Clinical Forms .............. 26 3.2.1 Seasonal and Perennial Allergic Conjunctivitis ...... 26 3.2.2 Vernal Keratoconjunctivitis .. 26 3.2.3 Atopic Keratoconjunctivitis .. 28 3.2.4 Giant Papillary Conjunctivitis 29 3.2.5 Contact Blepharoconjunctivitis ...... 29 3.3 Diagnosis .................. 30 3.3.1 Diagnostic Assays in Ocular Allergy .................... 30 3.3.1.1 Skin-Prick Test ............. 30 3.3.1.2 Patch Test ................. 31 3.3.2 In Vitro Assays .............. 31 3.3.3 LocalTests ................. 31 3.3.3.1 Conjunctival Provocation Test or Conjunctival Allergen Challenge .................. 31 3.3.3.2 Measurement of Specific IgE in Tears .................... 32 3.3.3.3 Measurement of Total IgE in Tears ...................... 32 3.3.3.4 Conjunctival Cytodiagnosis .. 32 3.3.3.5 Tear Chemical Mediator Measurement ............. 33 3.4 Immunopathogenesis ...... 33 ЗАЛ Sensitization ............... 34 3.4.2 Allergic Response .......... 34 3.5 Treatment of Ocular Allergy .. 37 3.5.1 Anti-Allergic Medication ___ 38 3.5.1.1 Vasoconstrictors ............ 38 3.5.1.2 Antihistamines ............. 38 3.5.1.3 Systemic Antihistamines ___ 38 3.5.1.4 Mast Cell Stabilizers ........ 38 3.5.1.5 Dual Action Anti-Allergic Molecules ..... 39 3.5.1.6 Nonsteroidal Anti- Inflammatory Drugs ........ 39 3.5.1.7 Corticosteroids ............. 39 3.5.1.8 Immunomodulators ........ 40 3.5.2 Nonpharmacological Management .............. 40 3.5.3 Surgical Treatment ......... 41 References ................. 41 Chapter 4 Current Aspects of the Immunobioiogy and Prevention of Corneal Graft Rejection: What Have We Learned from 100 Years of Keratopiasty? X.Q. Li, S. Schiickeiser, U. Pleyer 4.1 Introduction ............... 46 4.1 Л History and Prevalence of Allograft Rejection ......... 46 4.1.2 Local Immunologicai Features oftheCornea .............. 46 4.1.2.1 Corneal Immunogenicity ___46 4.1.2.2 Immune Privilege .......... 48 4.1.2.3 Anterior Chamber-Associated Immune Deviation ......... 50 4.2 Mechanisms of Corneal Allograft Rejection ......... 50 4.2.1 Antigen Presentation ....... 5Î 4.2.1.1 Antigen-Presenting Cells ___ 57 4.2.1.2 Direct/Indirect Pathway of Antigen Presentation ....... 57 4.2.2 Τ Cell Activation: Principle of Costimulation ..... 53 4.2.2.1 согв-собо/собб Costimulatory Signal Pathway .......... 53 4.2.2.2 CD40-CD154(CD40L) Costimulatory Signal Pathway ................... 53 4.2.3 Role of Immune Cells and Molecular Mediators in Graft Rejection .......... 55 4.2.3.1 Cellular Infiltration .......... 55 4.2.3.2 Molecular Mediators ........ 55 4.2.4 ТМЯіі2 Paradigm .......... 57 4.2.5 Role of Draining Cervical Lymph Nodes in Corneal Allograft Rejection ......... 58 4.2.6 RoleofCytotoxicT Lymphocyte Response in Corneal Graft Rejection ... 58 4.3 Strategies for the Prevention of Allograft Rejection ....... 60 4.3.1 UseofHLA-matched Transplants ............ 60 4.3.2 Immunmodulatory Agents in Keratopiasty ............... 62 4.3.2.1 Care of Normal-Risk Keratopiasty Patients ....... 62 4.3.2.2 Care of High-Risk Keratopiasty Patients .................. 65 4.3.3 Future Aspects: Immunologicai and Gene Therapy Approaches ....... 68 4.3.3.1 Monoclonal Antibodies and Other Biologicals .......... 68 4.3.3.2 Gene Therapy ...... 68 References ................. 69 Chapter 5 Autoimmune Keratitis lohn D. Gottsch 5.1 introduction ............... 77 5.2 Background ................ 78 5.2.1 Differential Diagnosis of Patient with Stromai Thinning Ulcération ................. 78 Contents XI 5.2.2 Laboratory Tests ........... 78 5.3 Autoimmune Keratitis ...... 79 5.3.1 Mechanisms of Autoimmune Keratopathy ............... 79 5.3.2 Rheumatoid Arthritis ....... 79 5.3.3 Rheumatoid Peripheral Ulcerative Keratitis ......... 80 5.3.3.1 Diagnosis .................. 80 5.3.3.2 Treatment ................. 80 5.3.4 Rheumatoid Paracentral Ulcerative Keratitis ......... 81 5.3.5 Scleritis-Associated Peripheral Keratopathy ............... 81 5.3.6 Postsurgical Ulcerative Keratitis ................... 82 5.3.7 Sjögren s Syndrome ........ 82 5.3.8 Wegener s Granulomatosis .. 83 5.3.9 Polyarteritis Nodosa ........ 83 5.3.10 Systemic Lupus Erythematosus ............. 83 5.3.11 Relapsing Polychondritis .... 84 5.3.12 Mooren s Ulcer ............. 84 5.4 Systemic Immunosuppression in Autoimmune Keratitis ___ 85 5.4.1 Classification of Immunosuppressive Drugs .. 85 5.4.1.1 Antimetabolites ............ 86 5.4.1.2 Alkylating Agents .......... 86 5.4.1.3 Τ Cell Inhibitors ............ 86 5.4.1.4 Proinflammatory Cytokine Antibodies ................. 86 5.5 Surgical Intervention in Autoimmune Keratitis ___ 86 5.5.1 Gluing ..................... 86 5.5.2 Cornea! Patch Grafting ...... 87 5.5.3 Ulcération in the Setting of a Patch Graft ................. 87 5.6 Conclusions ................ 88 References ................. 88 Chapter 6 Recent Developments in Herpes Stromai Keratitis Gregory M. Frank, Robert L. Hendricks 6.1 Introduction ............... 92 6.2 HSV-1 Latency and Recurrent HSK ....................... 92 6.3 Murine Model of HSK ....... 93 6.4 Τ Lymphocyte Involvement in HSK ....................... 94 6.5 Antigen Presentation in HSK 95 6.6 Cytokines and Chemokines in HSK ....................... 96 6.7 New Experimental Approaches to Treating HSK 97 References ................. 98 Chapter 7 Genetic Insights into Uveitis Friederike Mackensen, Zili Zhang, Tammy M. Martin, James T. Rosenbaum 7.1 Introduction .............. 707 7.1.1 Overview ................. 707 7.1.2 General Approaches to Genetic Study ............. 102 7.2 Uveitis Associated with Human Leukocyte Antigen Genes .................... 703 7.2.1 What Is the Human Leukocyte Antigen? ....... 703 7.2.2 From HLA Association to Disease? .................. 703 7.2.3 HLA-AssociatedUveitis .... 104 7.2.3.1 Acute Anterior Uveitis ..... 704 7.2.3.2 Chronic Anterior Uveitis in Juvenile-Onset Arthritis .... 704 7.2.3.3 ParsPlanitis ............... 704 7.2.3.4 Birdshot Retinochoroidopathy ...... 706 7.3 Uveitis Associations with Nort- HLA Genes ................ 706 7.3.1 Tumor Necrosis Factor Alpha .................... 7Ö6 7.3.2 Interferons ................ 707 7.3.3 CARDI 5/NOD2 ............ 108 7.4 Concluding Remarks ....... 709 References ................ 110 Chapter 8 Cataract Surgery in Patients with Ifveitis forge L. Alio, Javier A. Montero 8.1 Introduction .............. 773 8.2 Surgical Indication ......... 114 8.3 Patient Preparation ........ 7 75 8.4 Control of Inflammation ... 115 8.5 Surgical Procedure ........ 7 77 хи Contents 8.5.1 Choice of Intraocular Lens ..119 8.5.2 Combined Surgery ........ 727 8.5.2.1 Glaucoma ................ 121 2.2.2.2 Vitrectomy ................ 722 8.6 Postoperative Inflammation ............. 123 8.7 Complications ............ 124 8.8 Cataract Surgery in Specific Cases ..................... 125 8.8.1 Cataract Surgery in Children with Uveitis ............... 125 2.2.2 Phacoemulsifkation in Fuchs Heterochromic Cyclitis ..... 125 8.8.3 Ocular Toxoplasmosis ...... 126 8.8.4 Pars Planitis, Behcet s Disease, VKH Syndrome, and Multifocal Chorioretinitis ... 726 References ................ 727 Chapter 9 Ocular Toxoplasmosis Cristina Muccioli, Rubens Belfort Jr 9.1 Introduction .............. 732 9.2 Epidemiology ............. 132 9.3 Infection .................. 133 9.4 Clinical Features .......... 133 9.5 Ocular Disease ............ 733 9.5.1 Newboms with Congenital Disease ... 734 9.5.2 Signs Associated with Active Disease ................... 734 9.5.3 Course of Disease ......... 734 9.5.4 Immunosuppressed Patients .................. 734 9.6 Clinical Signs and Symptoms ................ 736 9.7 Serologìe Tests ............ 736 9.8 Imaging and Diagnostic Tests ..................... 737 9.8.1 Fluorescein Angiography .. 137 9.8.2 Indocyanine Green Angiography .............. 738 9.8.3 Optical Coherence Tomography .............. 738 9.8.4 Ultrasonography .......... 739 9.9 Pathology ................ 739 9.10 Treatment ................ 739 9.10.1 Goal ...................... 739 9.10.2 Antimtcrobiai Agents ...... 1 39 9.10.3 Corticosteroids ............ 740 9.10.4 Complications ............ 740 9.11 Disease in Immunosuppressed Patients .................. 747 9.11.1 Risk Factor ................ 747 9.11.2 Ocular Disease ............ 747 References ................ 742 Chapter 10 Vogt-Koyanagi-Harada Disease and Sympathetic Ophthalmia P. Kumar Rao, Narsing A. Rao 10.1 Introduction .............. 745 10.2 Vogt-Koyanagi-Harada Disease ................... 745 10.2.1 Historical Aspects ......... 746 10.2.2 Epidemiology ............. 746 10.2.3 Clinical Features ........... 746 10.2.4 Pathogenesis and Pathology ................ 749 10.2.5 Laboratory Investigations .. 750 10.2.6 Differential Diagnosis ...... 750 10.2.7 Treatment ................ 750 10.2.8 Prognosis and Complications ............ 757 10.3 Sympathetic Ophthalmia .. 757 10.3.1 Clinical Features ........... 752 10.3.2 Pathology and Pathogenesis ............. 752 10.3.3 Differential Diagnosis ...... 753 10.3.4 Therapy .................. 753 10.3.5 Complications and Prognosis ................. 753 References ................ 754 Chapter 11 Neoplastic Masquerade Syndromes Sarah E. Coupland 11.1 Introduction .............. 757 11.2 Lymphoid Malignancies ___ 758 11.2.1 Primary Intraocular Lymphoma ............... 758 11.2.1.1 Epidemiology of PIOL ...... 759 11.2.1.2 Symptoms and Signs ofPIOL ................... 759 11.2.1.3 Ophthalmic Findings in PIOL ................... 759 11.2.1.4 Diagnostic Techniques ..... 760 Contents ХШ 11.2.1.5 Laboratory Studies: 12.4.1 Posterior Segment Intraocular Cytological and Histological Inflammation ............. 184 Diagnosis in PIOL .......... 760 12.4.1.1 Behcet s Disease ........... 185 11.2.1.6 Biochemical and Molecular 12.4.1.2 Other Posterior Segment Analysis of PIOL ........... 762 Intraocular Inflammation ... 186 11.2.1.7 Treatment of PIOL ......... 763 12.4.2 Anterior Uveitis -Juvenile 11.2.1.8 Prognosisof PIOL .......... 164 IdiopathicArthritis and 11.2.2 Primary Uveal Lymphomas 164 Ankylosing Spondylitis ..... 186 11.2.2.1 Primary Choroidal 12.4.3 Other Ocular Inflammation 187 Lymphoma ............. 165 12.5 Caveats 1RS 11.2.2.2 Primary Iridai Lymphoma .. 166 12.5.1 Inhibition of Macrophage 11.2.2.3 Secondary Intraocular Function - Tuberculosis ___ 188 Lymphoma or Leukemia ... 167 12.5.2 Lymphoma Development .. 188 11.2.2.4 Post-Transplantation 12.5.3 Multiple Sclerosis and TNFa Lymphoproliferative Blockade ................. 7Я<5 Disorder .................. 167 12.5.4 Other Autoimmune Disease 11.3 Nonlymphoid Malignancies 167 and Autoantibody 11.3.1 Uveal Melanoma .......... 167 Production ............ ?«<? 11.3.2 Retinoblastoma ........... 167 12.5.5 Anti-Drug Antibodies ...... 790 11.3.3 Juvenile Xanthogranuloma 167 12.6 Future Directions .......... 790 11.3.4 Metastatic Tumors ......... 168 References ................ 191 11.3.4.1 Uveal Métastases .......... 168 11.3.4.2 Retinal Métastases ......... 168 Chapter 13 References ................ 169 Immune itheraov of Uveitis: is Gene Chapter^ Tumor Necrosis Factor Alpha-Targeted Therapies in Uveitis Susan Cochrane, Andrew D. Dick 12.1 Introduction .............. 777 12.2 Evidence of the Use of Anti- TNFa Agents .............. 778 12.2.1 What is TNFa? ............. 178 12.2.2 Rofe in the Immune Response ................. 178 12.2.3 Role in Uveitis - Data in Animals and Man .......... 778 12.2.3.1 Experimental Autoimmune Uveoretinitis .............. 778 12.2.3.2 Endotoxin-lnducedUveitis ..779 12.2.3.3 Clinical Uveitis ............ 779 12.3 Anti-TNFa Agents ......... 179 12.3.1 Neutralizing Antibodies ... 780 12.3.1.1 inffiximab ................. 180 12.3.1.2 Adalimumab .............. 181 12.3.2 Fusion Proteins ........... 785 12.3.2.1 Etanercept ................ 785 12.3.2.2 Other Fusion Proteins ...... 785 12.4 Studies in Uveitis .......... 785 Therapy in our Future? Rachel R. Caspi 13.1 Human Inflammatory Uveitis of Putative Autoimmune Origin .................... 193 13.2 Experimental Autoimmune Uveoretinitis - a Model for Human Autoimmune Uveitis .................... 194 13.3 Immunotherapeutic Paradigms: Antigen-Specific vs. Non-Antigen-Specific; Systemic vs. Local ......... 7 98 13.4 Gene Therapy as an Approach to Immunotherapy ........ 799 13.4.1 Gene Therapy of EAU by Peripheral Expression of a Uveitogenic Retinái Antigen .................. 799 13.4.1.1 Cellular Therapy with Autologous В Cells Expressing a Uveitogenic Epitope .....202 13.4.1.2 DNA Vaccination for Tolerance .................203 XIV Contents 13.4.2 Local Transfer into the Eye of Genes Encoding lmmunoinhibitory Molecules ................ 204 13.4.3 RNA Interference as a Future Prospect .................. 206 13.5 Conclusions ............... 207 Acknowledgements ....... 207 References ................ 207 Chapter 14 Optic Neuritis from the Perspective of an Ophthalmologist Klaus Ruether 14.1 Introduction .............. 211 14.2 Pathogenesis ............. 212 14.2.1 Pathology and Immunology 212 14.2.2 Relationship Between Optic Neuritis and Multiple Sclerosis .................. 213 14.3 Diagnosis ................. 213 14.3.1 Ophthalmologic ........... 213 14.3.2 Non-Ophthalmologic Diagnostic Tools ........... 279 14.4 Treatment ................ 220 14.4.1 Natural Course ............ 220 14.4.2 High-Dose Methylprednisolone ....... 220 14.4.3 Immunomodulation ....... 227 References ................ 222 Subject Index ................ 225
any_adam_object	1
author2	Pleyer, Uwe 1957-
author2_role	edt
author2_variant	u p up
author_GND	(DE-588)111452120
author_facet	Pleyer, Uwe 1957-
building	Verbundindex
bvnumber	BV035426534
classification_rvk	YO 7622
ctrlnum	(OCoLC)633642010 (DE-599)BVBBV035426534
discipline	Medizin
format	Book
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01898nam a2200505 c 4500</leader><controlfield tag="001">BV035426534</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20220909 </controlfield><controlfield tag="007">t\|</controlfield><controlfield tag="008">090407s2007 gw \|\|\|\| 00\|\|\| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">06,A48,1122</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783540307976</subfield><subfield code="9">978-3-540-30797-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3540307974</subfield><subfield code="9">3-540-30797-4</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783540307976</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">11543800</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)633642010</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV035426534</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YO 7622</subfield><subfield code="0">(DE-625)153957:12928</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WW 240</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Uveitis and immunological disorders</subfield><subfield code="b">with 22 tables</subfield><subfield code="c">ed.: Uwe Pleyer ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin [u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">2007</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Essentials in ophthalmology</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Augenentzündung</subfield><subfield code="0">(DE-588)4137370-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pathogenese</subfield><subfield code="0">(DE-588)4115512-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Uveitis</subfield><subfield code="0">(DE-588)4062232-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Augenentzündung</subfield><subfield code="0">(DE-588)4137370-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Pathogenese</subfield><subfield code="0">(DE-588)4115512-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Uveitis</subfield><subfield code="0">(DE-588)4062232-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pathogenese</subfield><subfield code="0">(DE-588)4115512-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pleyer, Uwe</subfield><subfield code="d">1957-</subfield><subfield code="0">(DE-588)111452120</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="z">978-3-540-30798-3</subfield><subfield code="w">(DE-604)BV022401690</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017346988&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-017346988</subfield></datafield></record></collection>
genre	(DE-588)4143413-4 Aufsatzsammlung gnd-content
genre_facet	Aufsatzsammlung
id	DE-604.BV035426534
illustrated	Not Illustrated
indexdate	2024-12-20T13:32:14Z
institution	BVB
isbn	9783540307976 3540307974
language	English
oai_aleph_id	oai:aleph.bib-bvb.de:BVB01-017346988
oclc_num	633642010
open_access_boolean
owner	DE-355 DE-BY-UBR DE-578
owner_facet	DE-355 DE-BY-UBR DE-578
publishDate	2007
publishDateSearch	2007
publishDateSort	2007
publisher	Springer
record_format	marc
series2	Essentials in ophthalmology
spellingShingle	Uveitis and immunological disorders with 22 tables Augenentzündung (DE-588)4137370-4 gnd Pathogenese (DE-588)4115512-9 gnd Uveitis (DE-588)4062232-0 gnd
subject_GND	(DE-588)4137370-4 (DE-588)4115512-9 (DE-588)4062232-0 (DE-588)4143413-4
title	Uveitis and immunological disorders with 22 tables
title_auth	Uveitis and immunological disorders with 22 tables
title_exact_search	Uveitis and immunological disorders with 22 tables
title_full	Uveitis and immunological disorders with 22 tables ed.: Uwe Pleyer ...
title_fullStr	Uveitis and immunological disorders with 22 tables ed.: Uwe Pleyer ...
title_full_unstemmed	Uveitis and immunological disorders with 22 tables ed.: Uwe Pleyer ...
title_short	Uveitis and immunological disorders
title_sort	uveitis and immunological disorders with 22 tables
title_sub	with 22 tables
topic	Augenentzündung (DE-588)4137370-4 gnd Pathogenese (DE-588)4115512-9 gnd Uveitis (DE-588)4062232-0 gnd
topic_facet	Augenentzündung Pathogenese Uveitis Aufsatzsammlung
url	http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=017346988&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
work_keys_str_mv	AT pleyeruwe uveitisandimmunologicaldisorderswith22tables

Verfügbarkeit

‌

Inhaltsverzeichnis